Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)
Phase 4
Completed
- Conditions
- Drug Usage
- Interventions
- Device: laryngeal mask airway (LMA)
- Registration Number
- NCT01931683
- Lead Sponsor
- Ajou University School of Medicine
- Brief Summary
The investigators attempted to determine the optimal effect-site concentration of remifentanil for smooth removal of the LMA from propofol anesthesia.
- Detailed Description
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). LMA removal was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- ASA I-II patients undergoing general anesthesia for short elective surgery (<1 hr)
Exclusion Criteria
- G-E reflux
- obesity (BMI>30)
- anticipated difficult airway
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description remifentanil laryngeal mask airway (LMA) LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods. remifentanil remifentanil LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
- Primary Outcome Measures
Name Time Method smooth removal of LMA from end of surgery to removal of LMA (participants will be followed for the emergence periods, an expected average of 15 min). the response of patients to the removal of LMA (classified as either 'success \[smooth emergence\]' or 'failure') during infusion of remifentanil.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ajou University School of Medicine
🇰🇷Suwon, Korea, Republic of